Respiratory Syncytial Virus (RSV) Infections – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Respiratory Syncytial Virus (RSV) Infections – Pipeline Review, H2 2017’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections

The report reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Respiratory Syncytial Virus (RSV) Infections therapeutics and enlists all their major and minor projects

The report assesses Respiratory Syncytial Virus (RSV) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3-V Biosciences Inc

Abivax SA

Ablynx NV

ADMA Biologics Inc

Agilvax Inc

Amarillo Biosciences Inc

Anima Biotech Ltd

Aridis Pharmaceuticals LLC

Artificial Cell Technologies Inc

AstraZeneca Plc

Aviragen Therapeutics Inc

Bavarian Nordic A/S

Celltrion Inc

Curevac AG

DBV Technologies SA

Enanta Pharmaceuticals Inc

Evec Inc

F. Hoffmann-La Roche Ltd

Gene Techno Science Co Ltd

GenVec Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Globavir Biosciences Inc

iBio Inc

Immunovaccine Inc

Immunwork Inc

Inovio Pharmaceuticals Inc

Johnson & Johnson

Karyopharm Therapeutics Inc

Kineta Inc

mAbxience SA

MedImmune LLC

Medivir AB

Merck & Co Inc

Mucosis BV (Inactive)

Mymetics Corp

NanoBio Corp

Navigen Inc

Novavax Inc

Phoenix Biotechnology Inc

Profectus BioSciences Inc

Pulmocide Ltd

ReViral Ltd

Romark Laboratories LC

Sanofi

Takeda Pharmaceutical Co Ltd

TechnoVax Inc

Themis Bioscience GmbH

Vault Pharma Inc

Vaxart Inc

VBI Vaccines Inc

Virometix AG

Visterra Inc

VLP Biotech Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Respiratory Syncytial Virus (RSV) Infections - Overview 6

Respiratory Syncytial Virus (RSV) Infections - Therapeutics Development 7

Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment 24

Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development 32

Respiratory Syncytial Virus (RSV) Infections - Drug Profiles 57

Respiratory Syncytial Virus (RSV) Infections - Dormant Projects 225

Respiratory Syncytial Virus (RSV) Infections - Discontinued Products 229

Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones 230

Appendix 241

List of Tables

List of Tables

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2017 20

Number of Products under Development by Companies, H2 2017 22

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 23

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 24

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 25

Number of Products under Development by Universities/Institutes, H2 2017 26

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 28

Products under Development by Companies, H2 2017 29

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 30

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 31

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 32

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 33

Products under Development by Universities/Institutes, H2 2017 34

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 36

Number of Products by Stage and Target, H2 2017 38

Number of Products by Stage and Mechanism of Action, H2 2017 40

Number of Products by Stage and Route of Administration, H2 2017 42

Number of Products by Stage and Molecule Type, H2 2017 44

Respiratory Syncytial Virus (RSV) Infections – Pipeline by 3-V Biosciences Inc, H2 2017 45

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Abivax SA, H2 2017 45

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Ablynx NV, H2 2017 46

Respiratory Syncytial Virus (RSV) Infections – Pipeline by ADMA Biologics Inc, H2 2017 46

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Agilvax Inc, H2 2017 47

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Amarillo Biosciences Inc, H2 2017 47

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Anima Biotech Ltd, H2 2017 47

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Aridis Pharmaceuticals LLC, H2 2017 48

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Artificial Cell Technologies Inc, H2 2017 48

Respiratory Syncytial Virus (RSV) Infections – Pipeline by AstraZeneca Plc, H2 2017 49

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Aviragen Therapeutics Inc, H2 2017 49

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Bavarian Nordic A/S, H2 2017 50

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Celltrion Inc, H2 2017 50

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Curevac AG, H2 2017 51

Respiratory Syncytial Virus (RSV) Infections – Pipeline by DBV Technologies SA, H2 2017 51

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Enanta Pharmaceuticals Inc, H2 2017 52

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Evec Inc, H2 2017 52

Respiratory Syncytial Virus (RSV) Infections – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 52

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Gene Techno Science Co Ltd, H2 2017 53

Respiratory Syncytial Virus (RSV) Infections – Pipeline by GenVec Inc, H2 2017 53

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Gilead Sciences Inc, H2 2017 54

Respiratory Syncytial Virus (RSV) Infections – Pipeline by GlaxoSmithKline Plc, H2 2017 55

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Globavir Biosciences Inc, H2 2017 55

Respiratory Syncytial Virus (RSV) Infections – Pipeline by iBio Inc, H2 2017 56

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Immunovaccine Inc, H2 2017 56

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Immunwork Inc, H2 2017 56

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Inovio Pharmaceuticals Inc, H2 2017 57

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Johnson & Johnson, H2 2017 58

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Karyopharm Therapeutics Inc, H2 2017 58

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Kineta Inc, H2 2017 59

Respiratory Syncytial Virus (RSV) Infections – Pipeline by mAbxience SA, H2 2017 59

Respiratory Syncytial Virus (RSV) Infections – Pipeline by MedImmune LLC, H2 2017 59

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Medivir AB, H2 2017 60

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Merck & Co Inc, H2 2017 60

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Mucosis BV (Inactive), H2 2017 61

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Mymetics Corp, H2 2017 61

Respiratory Syncytial Virus (RSV) Infections – Pipeline by NanoBio Corp, H2 2017 62

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Navigen Inc, H2 2017 62

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Novavax Inc, H2 2017 62

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Phoenix Biotechnology Inc, H2 2017 63

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Profectus BioSciences Inc, H2 2017 63

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Pulmocide Ltd, H2 2017 64

Respiratory Syncytial Virus (RSV) Infections – Pipeline by ReViral Ltd, H2 2017 64

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Romark Laboratories LC, H2 2017 64

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Sanofi, H2 2017 65

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 65

Respiratory Syncytial Virus (RSV) Infections – Pipeline by TechnoVax Inc, H2 2017 66

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Themis Bioscience GmbH, H2 2017 66

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vault Pharma Inc, H2 2017 67

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vaxart Inc, H2 2017 67

Respiratory Syncytial Virus (RSV) Infections – Pipeline by VBI Vaccines Inc, H2 2017 67

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Virometix AG, H2 2017 68

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Visterra Inc, H2 2017 68

Respiratory Syncytial Virus (RSV) Infections – Pipeline by VLP Biotech Inc, H2 2017 69

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, H2 2017 238

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, H2 2017 (Contd..1), H2 2017 239

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, H2 2017 (Contd..2), H2 2017 240

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, H2 2017 (Contd..3), H2 2017 241

Respiratory Syncytial Virus (RSV) Infections – Discontinued Products, H2 2017 242

List of Figures

List of Figures

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2017 20

Number of Products under Development by Companies, H2 2017 21

Number of Products under Development by Universities/Institutes, H2 2017 26

Number of Products by Top 10 Targets, H2 2017 37

Number of Products by Stage and Top 10 Targets, H2 2017 37

Number of Products by Top 10 Mechanism of Actions, H2 2017 39

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 39

Number of Products by Routes of Administration, H2 2017 41

Number of Products by Stage and Routes of Administration, H2 2017 41

Number of Products by Top 10 Molecule Types, H2 2017 43

Number of Products by Stage and Top 10 Molecule Types, H2 2017 43

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports